To assess the molecular epidemiology of human immunodeficiency virus type 1 (HIV-1), a screening method was developed for identification of non-B subtypes from sequence data obtained for resistance testing. The method is based on the evaluation of the percentage of divergence of a given sequence from the reference B subtype HXB2. Analysis of 1720 reverse-transcriptase (RT) and 1824 protease sequences stored in a database allowed for the determination of a threshold level of divergence from HXB2 above which a non-B subtype could be unambiguously characterized regardless of the pattern of resistance mutations (18.6% for RT; 110.8% for protease). This conclusion was validated by phylogenetic analysis of RT, protease, and env genes. Overall, 72 (4.2%) and 73 (4.0%) non-B sequences were identified in the RT and protease coding regions, respectively. This method allows for the rapid detection of non-B subtypes among retrospective, recent, and future RT and/or protease sequence databases.
Use of Drug Resistance Sequence Data for the Systematic Detection of Non-B Human Immunodeficiency Virus Type 1 (HIV-1) Subtypes: How to Create a Sentinel Site for Monitoring the Genetic Diversity of HIV-1 at a Country Scale
Genetic strain surveillance has increased rapidly in recent years and is useful for delineating the presence of different sequence subtypes around the world and the specific dynamics of regional epidemics [1] . Nevertheless, the current worldwide distribution of human immunodeficiency virus type 1 (HIV-1) subtypes needs to be better established, to track changes of subtype distribution over time, to detect the introduction of novel subtypes into study populations, and, eventually, to facilitate vaccine development [2, 3] . In France, most HIV-1 isolates belong to group M, subtype B. However, large-scale screening in several French hospitals enabled the detection of all non-B subtypes, as recently reported by the AC11 network of the French agency for AIDS research [4] . This suggests that most HIV-1 subtypes have entered France and that the prevalence of non-B subtypes circulating in this country might be higher than previously thought.
Unfortunately, the detection of non-B subtypes is based on specific methodologies that are time-consuming and may be difficult to develop as routine assays in clinical laboratories. These methods generally are based on an analysis of the env gene (by sequencing or by heteroduplex mobility assay) or on the detection of antibodies against the third variable (V3) domain of HIV-1 gp120 [5] . Consequently, the actual prevalence of non-B subtypes in a given population may be underestimated, thereby delaying both the detection of new emerging subtypes and the progressive changes in subtype distribution [6] [7] [8] .
A worldwide effort has been made by the scientific community to sequence reverse-transcriptase (RT) and protease genes from clinical samples, to identify drug resistance mutations and to adapt treatment strategies accordingly [9, 10] . This prompted us to analyze the pol sequences stored in our own database, which was developed during the follow-up of infected patients in Marseille hospitals. Since epidemiologic surveillance can be incorporated most easily into existing studies, we questioned whether the sequences stored in this database could be incidentally used to identify non-B HIV-1 subtypes. We analyzed 1720 RT and 1824 protease sequences.
Materials and Methods
Study samples. Blood specimens from patients attending HIV-AIDS reference hospitals in Marseille, France, were collected from 1997 to 2000. In this study, we reviewed 1720 RT sequences (1284 patients) and 1824 protease sequences (1325 patients).
Polymerase chain reaction (PCR) and sequencing. Total nucleic acid was extracted from plasma with the QIAamp viral RNA kit (Qiagen), as directed by the manufacturer's protocol. Nucleic acid was eluted in 50 mL of ribonuclease-free water and was stored at Ϫ70ЊC. The 5 part of the RT encoding the first 239 aa and the entire protease gene were generated by nested PCR, as described elsewhere [11] , or by an HIV-1 genotyping system (Viroseq; Applied Biosystems). The codons assessed for genotypic changes were described by Hirsch et al. [12] in both the protease and RT genes. HIV-1 subtypes were characterized by examining a fragment within the env gene covering the V3-V5 region, which was amplified by nested PCR. Resistance-associated mutations of human immunodeficiency virus type 1 RT considered in this study were described by an international AIDS panel [12] .
First-round primers were ED5 and ED12 [13] . Second-round primers were ES7 and ES8 [14] . To avoid PCR product cross-contamination, pre-PCR and post-PCR manipulations were done in separate rooms. PCR products were sequenced directly in both directions with fluorescent dye-labeled sequencing terminators (dye terminator cycle sequencing with AmpliTaq DNA polymerase FS; Applied Biosystems). Electrophoresis and data collection were done by using an automatic DNA sequencer (model 377; Applied Biosystems).
Phylogenetic analysis. For subtype determination, the RT and protease regions were taken from representative strains of HIV-1 group M or group O subtypes available in the Los Alamos database [15] . Alignments were generated by CLUSTAL W (version 1.8) software [16] . Phylogenetic analysis was done with the Phylip software package [17] . Evolutionary distances were estimated by using the Dnadist (Kimura 2-parameter method), and phylogenetic relations were determined by using the neighbor-joining method. Reproducibility of branching pattern was determined by Seqboot (bootstrap method: 100 replicates) [17] . The sequence of O-MVP5180 was used as the out group. We assessed the robustness of the trees by analyzing sequential samples from a same patient, which formed, in each case, an individual branch with a bootstrap of 100 (e.g., samples M12 and M75 or M18 and M81 in the RT gene).
Database. Sequence data were stored in a specifically designed database (Microsoft Access 97) that allowed for the retrieval of genotypes on the basis of the absence or presence of any combination of resistance-associated mutations [9, 11] . The percentage of divergence from HXB2 (GenBank accession no. K03455) was generated automatically after aligning the clinical sequence with the reference. In this analysis, codons 16-239 for the RT and 1-99 for the protease were considered. The percentage of divergence was expressed as discrete values that represent the mean of each group (i.e., 0.5%-1.4% for the group with a 1% divergence). All non-B sequences in this study were submitted to GenBank (accession nos. AY010328-AY010369, AY010370-AY010437, and AY010438-AY010504 for env, protease, and RT sequences, respectively).
Results
The routine genotype characterization of HIV-1 strains from infected patients generally is based on the sequencing of plasma HIV-1 RNA in the RT and protease coding regions. For detecting resistance-associated mutations in the clinical cohorts followed in Marseille, each sequence is put into a specifically designed database, in which it is compared with the corresponding HXB2 reference sequence to identify drug resistance mutations. This also enables us to determine the level of divergence between the patient's sequence and HXB2, which is automatically calculated by the software. For the RT gene of 1720 samples from 1284 patients, the percentage of divergence from HXB2 varied from 1.2% to 12.2%, and we determined 12 discrete groups of divergence, as shown in figure 1A .
Since most of the study patients received antiretroviral therapy, it could be argued that the high variability of RT genomes reflected the accumulation of resistance-associated mutations. To investigate this point, we analyzed the distribution of such mutations over the 12 groups of divergence defined above (results are shown in figure 1B) . Although the prevalence of resistance mutations increased initially with the percentage of divergence of the sequence, this was obviously not so for the groups that had a percentage of divergence 18%. Therefore, the high variability of these RT sequences, compared with that of the reference HXB2 sequence, could not be just related to a polymutated resistance profile. Thus, an alternative explanation for this variability could be the presence of non-B subtypes in the population studied.
To test this hypothesis, we conducted a phylogenetic analysis of the 1720 RT sequences in our database. Of these, 1648 (95.8%) clustered with characteristic subtype B reference samples, whereas 72 (4.2%) were unambiguously outside. Of interest, the totality of these 72 non-B subtypes in the RT gene diverged 15.6% from HXB2 RT ( figure 2, black histograms) . Between 5.6% and 7.0%, 6 non-B subtypes (all subtype D) were characterized. As shown in figure 2 , the prevalence of non-B subtype RT sequences increased with the percentage of divergence from HXB2. Although the accumulation of mutations contributed to increased distance from HXB2, polymutated subtype B RT always were found in the sequence group that had !8.6% of divergence. Therefore, sequences that had 18.6% of divergence corresponded to non-B subtypes. Figure 3A shows the phylogenetic analysis of the 72 non-B subtypes identified by this method. These RT sequences were distributed over 6 distinct groups. Forty-five sequences clustered with subtypes A (20 samples), D (10 samples, among which were the 2 sequences with 5.6% divergence; figure 2), C (8 samples), F (4 samples), and J (3 samples). Eighteen sequences clustered with the reference strains from genetic subtype AG. Of note, for the pol gene, the reference viruses for subtype A could include either A (e.g., U455) or AE (e.g., CM240) strains, as shown by Carr et al. [18] . Finally, a cluster of 9 sequences was clearly distinct from the B subtype but could not be assigned to any of the reference subtypes, although it appeared to be preferentially linked to subtype A. In Figure 3A , these sequences are referred to as NA.
In a similar analysis with the protease sequence data available in our database (1824 HIV-1 sequences from 1325 patients), divergence from the protease gene of HXB2 varied from 1.0% to 14.8%. The phylogenetic analysis of these samples allowed us to identify 73 (4.0%) non-B subtype protease sequences (figure 3B). As for RT sequences, the main non-B subtype in the protease gene was subtype A (24 samples). The other sequences clustered as follows: subtype AG (20 samples), D (8 samples), C (11 samples), F (4 samples), and J (2 samples). There were also 4 nontypeable sequences (NA) that clustered apart from the above-mentioned subtypes. These sequences were linked to subtype C. Figure 2 (hatched histograms) shows the distribution of the 73 non-B subtypes by the percentage of divergence from HXB2. In all cases, non-B subtype sequences had 17.4% of divergence. For subtype D, which is phylogenetically close to subtype B, divergence from HXB2 protease gene was 7.5%-10.4%. As for the RT gene, it appeared that, above this threshold value, non-B subtype protease sequences increased with the percentage of divergence from HXB2. All protease sequences that had 110.8% of divergence were non-B subtype.
To investigate further the subtype distribution of the HIV-1 strains identified on the basis of sequence data variability in the pol gene and the presence of potential recombinants, we conducted sequence and phylogenetic analyses on the V3-V5 coding region of the env gene ( figure 3C ). Data from 37 of these non-B samples are compared in figure 3 and table 1. In perfect agreement with the data obtained by analysis of the RT ( figure  3A ) and protease (figure 3B) coding regions, the env sequence of all 37 samples clearly was distinct from the B subtype ( figure  3C ). Concordant results for the 3 coding regions were obtained in 27 (73%) cases (table 1) 
Discussion
Our major finding is that HIV-1 pol sequences obtained in clinical laboratories to identify resistance-associated mutations can be used to screen for circulating non-B subtypes. In the south of France, including the Marseille area, it has been possible by these means to determine a threshold level of divergence from HXB2 above which a non-B subtype could be suspected (15.6% for RT; 17.4% for protease) or unambiguously diagnosed (18.6% for RT; 110.8% for protease), regardless of the resistance mutation pattern. This conclusion, which was based on the analysis of 1720 RT and 1824 protease sequences stored in our database, was validated by a comparative phylogenetic analysis of RT, protease, and env sequences. When the sequence of the pol gene belonged to a non-B subtype, the sequence of its env gene (V3-V5 coding region) was also non-B, as demonstrated for a subpopulation of 37 patients whose viruses were sequenced in both pol and env. This confirmation is particularly important for subtype D, which is related phylogenetically to subtype B ( figure 3) . Nevertheless, subtypes B and D were entirely distinguishable in the phylogenetic analysis of the env gene (bootstrap values of 99 and 89 for B and D clusters, respectively, figure 3C ). Moreover, the assignment of the genetic subtype, derived from the analysis of RT, protease, and V3-V5 sequences, was concordant in 27 (73%) of these 37 samples. For the remaining samples, the env coding region clustered generally with subtype AG, whereas the pol sequences could be either A or nontypeable (NA; table 1). Nontypeable sequences in the protease gene may be due to an unusual phylogenetic relationship among subtypes A, G, AE, and AG, as pointed out by Carr et al. [18] . Of note, in all cases, the phylogenetic analysis confirmed the identification of a non-B subtype that was suggested by the percentage of divergence of a pol sequence from the reference HXB2. The threshold value of this percentage was slightly higher for the protease gene (10.8%) than for the RT gene (8.6%). This is in agreement with the natural polymorphism of the protease gene, which is less conserved than the 5 half of the RT gene [19, 20] . However, our data support the recent observation that, despite this high variability, protease sequences from non-B subtypes may display specific mutation patterns [21] . Thus, it is of interest that the divergence between the pol gene sequence of clinical isolates and the HXB2 reference was not only due to the presence of drug resistance mutations, as shown in figure 2 . Overall, these data suggest that the divergence of a clinical isolate from HXB2 (at least in the RT and/or protease coding regions) reflects specific mutational patterns that may enable distinguishing between B and non-B HIV-1 subtypes. Therefore, we suggest that the percentage of divergence of a given pol sequence from the reference HXB2 is a key to alert the physician of the presence of a non-B subtype. It is critical for physicians to suspect and diagnose non-B subtypes, because the replication of non-B subtypes may not be accurately measured, despite the significant improvement of commercial assays [22] . In addition, the nature of the subtype may affect the response to antitretroviral drugs, which may be the case for subtype G isolates that appeared to be less sensitive to protease inhibitors [23] .
Another important finding from this study is the high prevalence of non-B subtypes (4.2% in the RT gene, including potential recombinants) in the Marseille area. By comparison, in 5322 US samples sequenced in the pol gene, Wegner et al. [24] found only 8 (0.15%) non-B subtypes. The high percentage of non-B subtypes may be inherent to the geographic location of Marseille, a major Mediterranean port, and would explain why several HIV-1 subtypes and various classes of potential recombinants were detected in this city.
Our primary objective was to detect non-B subtypes in existing resistance databases. Therefore, our findings should not be considered as an indication of the true prevalence of non-B subtypes in the population. The study population was re- stricted to persons for whom a genotypic analysis was done. Thus, the suggestion of the cutoff for the percentage of divergence that suggests an unambiguous diagnosis of a non-B subtype would be applicable only to persons receiving treatment. Indeed, RT sequences belonging to the B subtype that display р13 resistance mutations have a maximal percentage of divergence of 8.4% from HXB2. For comparison, the subtype B RT genes of our database, which are devoid of resistance mutations, differed by !5.5% from HXB2.
In conclusion, we developed a strategy to detect non-B subtypes of HIV-1 from the analysis of pol sequences, which is routinely done to identify drug resistance mutations. The method also could be used retrospectively to RT and/or protease sequences in clinical databases [25] and thereby allow for the rapid identification of persons suspected of harboring non-B HIV-1 strains. By using the percentage of divergence from HXB2 as a statistical analysis method, one can screen several thousand sequences at the same time. Ideally, each center involved in HIV-1 sequencing could function as a sentinel site to provide an up-to-date estimate of the prevalence of non-B strains that circulate in the corresponding area. Collection of this information would allow for a rapid overview of the distribution of HIV-1 strains at a country scale, thereby facilitating the epidemiologic surveillance of HIV-1 infections.
